Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Blueprint Medicines (BPMC) Misses Q4 EPS by 7c, Revenues Miss
February 26, 2019 7:22 AM ESTBlueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.83), $0.07 worse than the analyst estimate of ($1.76). Revenue for the quarter came in at $1.03 million versus the consensus estimate of $1.68 million.
"Following a year of remarkable clinical progress across our portfolio in 2018, we are focused on... More
